All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

2015688 citationsJournal Articlehybrid Open Access

Authors

David R. Nelson · University of Florida

James N. Cooper · Inova Fairfax Hospital

Jacob Lalezari · Quest Clinical Research (United States)

Eric Lawitz · The University of Texas Health Science Center at San Antonio

Paul J. Pockros · Scripps Clinic

Norman Gitlin · Atlanta Gastroenterology Associates

Bradley Freilich

Abstract

A 12-week regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated. Additional evaluation to optimize efficacy in genotype 3-infected patients with cirrhosis is underway.

Topics & Keywords

Hepatitis C virus research HIV/AIDS drug development and treatment Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology

Volume 61, Issue 4, pp. 1127-1135

DOI: 10.1002/hep.27726

Field-Weighted Citation Impact: 74.05